Corvus Pharmaceuticals, Inc.CRVS
What Corvus Pharmaceuticals, Inc. does.
We are a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. We believe our proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers.
Our lead product candidate, soquelitinib (formerly CPI-818), is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. Based on the proposed mechanism of action, we believe soquelitinib has the potential to be utilized to inhibit the production of a number of inflammatory cytokines involved in diseases such as atopic dermatitis, hidradenitis suppurativa, asthma, psoriasis and fibrotic diseases. In preclinical studies, Soquelitinib has affected T cell differentiation leading to enhanced function of T cells involved in tumor cell eradication.
Since the immune cells targeted by our product candidates play a role in many diseases, our strategy is to leverage our research and development capabilities by evaluating our product candidates in clinical trials where there is an understanding of the role of specific T cells in the target indication and where we believe such product candidates have the broadest potential. We believe this strategy has enabled us to move rapidly from preclinical to clinical trials in diverse disease areas, each with large unmet needs. Soquelitinib entered both a registrational, Phase 3 clinical trial for relapsed T cell lymphomas and a recently initiated randomized, placebo-controlled Phase 2 trial in patients with atopic dermatitis. We have two additional product candidates which are in clinical development for the treatment of various solid tumors, also based on modulation of immune function.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$6.0M | -$43.2M | -$41.3M | -$27.0M | -$62.3M | -$15.3M |
| Free cash flow | -$34.9M | -$36.7M | -$27.3M | -$24.0M | — | -$33.0M |
More on CRVS.
- Corvus Pharmaceuticals, Inc. summary
- Corvus Pharmaceuticals, Inc. financial statements
- Corvus Pharmaceuticals, Inc. key metrics
- Corvus Pharmaceuticals, Inc. health scores and style box
- Corvus Pharmaceuticals, Inc. earnings
- Corvus Pharmaceuticals, Inc. dividends
- Corvus Pharmaceuticals, Inc. valuation
- Corvus Pharmaceuticals, Inc. ownership and insiders
- Corvus Pharmaceuticals, Inc. peers
Figures from Corvus Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.